An influenza virus vector candidate vaccine stably expressing SARS-CoV-2 receptor-binding domain produces high and long-lasting neutralizing antibodies in mice

文献类型： 外文期刊

第一作者： Zhao, Yongzhen

作者： Zhao, Yongzhen;Zhao, Lingcai;Li, Yingfei;Liu, Qingzheng;Deng, Lulu;Lu, Yuanlu;Zhang, Xiaoting;Li, Shengmin;Ping, Jihui;Ge, Jinying;Bu, Zhigao

作者机构：

关键词： Influenza virus vector; SARS-CoV-2; Influenza C virus; Receptor-binding domain; Live attenuated vaccine

期刊名称：VETERINARY MICROBIOLOGY （ 影响因子：3.246； 五年影响因子：3.565 ）

ISSN： 0378-1135

年卷期： 2022 年 271 卷

页码：

收录情况： SCI

摘要： Viral infectious pathogens, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus, can cause extremely high infection rates and mortality in humans. Therefore, it is urgent to develop an effective vaccine against coronavirus and influenza virus infection. Herein, we used the influenza virus as a vector to express the SARS-CoV-2 spike receptor-binding domain (RBD) and hemagglutinin-esterasefusion (HEF) protein of the influenza C virus. We then evaluated the feasibility and effectiveness of this design strategy through experiments in vitro and in vivo. The results showed that the chimeric viruses could stably express the HEF protein and the SARS-CoV-2 spike RBD at a high level. BALB/c mice, infected with the chimeric virus, exhibited mild clinical symptoms, yet produced high specific antibody levels against RBD and HEF, including neutralizing antibodies. Importantly, high neutralizing antibodies could be retained in the sera of mice for at least 20 weeks. Altogether, our data provided a new strategy for developing safe and effective COVID-19 and influenza virus vaccines.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序